File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00592-023-02177-x
- Scopus: eid_2-s2.0-85170221586
- WOS: WOS:001066395400001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI
Title | Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI |
---|---|
Authors | |
Keywords | Cardiac MRI Cardiovascular magnetic resonance Diabetes Diastolic function Feature tracking Heart failure Myocardial strain Saxagliptin |
Issue Date | 10-Sep-2023 |
Publisher | Springer |
Citation | Acta Diabetologica, 2023, v. 61, n. 1, p. 91-97 How to Cite? |
Abstract | AimsType 2 diabetes mellitus (T2DM) increases the risk of major cardiovascular events. In SAVOR-TIMI53 trial, the excess heart failure (HF) hospitalization among patients with T2DM in the saxagliptin group remains poorly understood. Our aim was to evaluate left ventricular (LV) diastolic function after 6 months of saxagliptin treatment using cardiac magnetic resonance imaging (CMR) in patients with T2DM.Methods In this prospective study, 16 T2DM patients without HF were prescribed saxagliptin as part of routine guideline-directed management. CMR performed at baseline and 6 months after initiation of saxagliptin treatment were evaluated in a blinded fashion. We assessed LV diastolic function by measuring LV peak filling rate with correction for end-diastolic volume (PFR/LVEDV), time to peak filling rate with correction for cardiac cycle (TPF/RR), and early diastolic strain rate parameters [global longitudinal diastolic strain rate (GLSR-E), global circumferential diastolic strain rate (GCSR-E)] by feature tracking (FT-CMR).ResultsAmong the 16 patients (mean age of 59.9, 69% males, mean hemoglobin A1c 8.3%, mean left ventricular ejection fraction 57%), mean PFR was 314 ± 108 ml/s at baseline and did not change over 6 months (− 2.7, 95% CI − 35.6, 30.2, p = 0.86). There were also no significant changes in other diastolic parameters including PFR/EDV, TPF, TPF/RR, and GLSR-E and GCSR-E (all p > 0.50).Conclusion In T2DM patients without HF receiving saxagliptin over 6 months, there were no significant subclinical changes in LV diastolic function as assessed by CMR. |
Persistent Identifier | http://hdl.handle.net/10722/341729 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.980 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, Kathy C K | - |
dc.contributor.author | Ismail, Huda S | - |
dc.contributor.author | Connelly, Kim A | - |
dc.contributor.author | Verma, Subodh | - |
dc.contributor.author | Ng, Ming-Yen | - |
dc.contributor.author | Deva, Djeven P | - |
dc.contributor.author | Yan, Andrew T | - |
dc.contributor.author | Jimenez-Juan, Laura | - |
dc.date.accessioned | 2024-03-20T06:58:37Z | - |
dc.date.available | 2024-03-20T06:58:37Z | - |
dc.date.issued | 2023-09-10 | - |
dc.identifier.citation | Acta Diabetologica, 2023, v. 61, n. 1, p. 91-97 | - |
dc.identifier.issn | 0940-5429 | - |
dc.identifier.uri | http://hdl.handle.net/10722/341729 | - |
dc.description.abstract | <p>AimsType 2 diabetes mellitus (T2DM) increases the risk of major cardiovascular events. In SAVOR-TIMI53 trial, the excess heart failure (HF) hospitalization among patients with T2DM in the saxagliptin group remains poorly understood. Our aim was to evaluate left ventricular (LV) diastolic function after 6 months of saxagliptin treatment using cardiac magnetic resonance imaging (CMR) in patients with T2DM.Methods In this prospective study, 16 T2DM patients without HF were prescribed saxagliptin as part of routine guideline-directed management. CMR performed at baseline and 6 months after initiation of saxagliptin treatment were evaluated in a blinded fashion. We assessed LV diastolic function by measuring LV peak filling rate with correction for end-diastolic volume (PFR/LVEDV), time to peak filling rate with correction for cardiac cycle (TPF/RR), and early diastolic strain rate parameters [global longitudinal diastolic strain rate (GLSR-E), global circumferential diastolic strain rate (GCSR-E)] by feature tracking (FT-CMR).ResultsAmong the 16 patients (mean age of 59.9, 69% males, mean hemoglobin A1c 8.3%, mean left ventricular ejection fraction 57%), mean PFR was 314 ± 108 ml/s at baseline and did not change over 6 months (− 2.7, 95% CI − 35.6, 30.2, p = 0.86). There were also no significant changes in other diastolic parameters including PFR/EDV, TPF, TPF/RR, and GLSR-E and GCSR-E (all p > 0.50).Conclusion In T2DM patients without HF receiving saxagliptin over 6 months, there were no significant subclinical changes in LV diastolic function as assessed by CMR.<br></p> | - |
dc.language | eng | - |
dc.publisher | Springer | - |
dc.relation.ispartof | Acta Diabetologica | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Cardiac MRI | - |
dc.subject | Cardiovascular magnetic resonance | - |
dc.subject | Diabetes | - |
dc.subject | Diastolic function | - |
dc.subject | Feature tracking | - |
dc.subject | Heart failure | - |
dc.subject | Myocardial strain | - |
dc.subject | Saxagliptin | - |
dc.title | Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s00592-023-02177-x | - |
dc.identifier.scopus | eid_2-s2.0-85170221586 | - |
dc.identifier.volume | 61 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 91 | - |
dc.identifier.epage | 97 | - |
dc.identifier.eissn | 1432-5233 | - |
dc.identifier.isi | WOS:001066395400001 | - |
dc.identifier.issnl | 0940-5429 | - |